(Income Generated on 47% Revenue Growth; Exploring Alternatives for its Natural Attraction Brand) SAN JOSE, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC:EROX) (BULLETIN BOARD: EROX) ("HPS" or "the Company") today announced results for the second quarter ended June 30, 2007. Net revenues of $329,000, represented a 79% increase from the revenues of $184,000 in the prior year period, and resulted in a net income of $15,000 ($.00 per share) as compared with a net loss of $156,000 ($.04 per share) for the same period of 2006. For the six month period, net revenues grew by 47% to $663,000 from $450,000 and the net income for the first six months of 2007 was $39,000 ($.01 per share) a $265,000 improvement from the 2006 net loss of $226,000 ($.05 per share) incurred in the first six months of the prior year. At June 30, 2007, basic liquidity (cash plus accounts receivable, less accounts payable and accrued expenses) were $1,715,000 as compared with $1,836,000 at December 31, 2006. "The second quarter increase in net revenue was attributable to an initial order of pheromones for a specialty retailer, and the recognition of revenue under the License Agreement signed last year with a Johnson & Johnson subsidiary. We are pleased to have revenue growth from an expanding customer base while we continue product development spending for two additional compounds that we have identified and isolated that are now in different stages of development. With respect to the new compounds in which we are investing, we are excited about the results we have seen to date, and the potential for these novel compounds. We expect to file for patent protection on one of the compounds in the United States in the third quarter," a Company spokesperson indicated. "We are also exploring several alternative options for the sales and marketing of its Natural Attraction(R) product line, which contains our proprietary mood-enhancing technology. The brand is not currently realizing its potential and we feel strongly that using outside resources to assist in the repositioning, and promotion of this brand will be beneficial for the business," the Company noted. Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of-concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at http://www.erox.com/. The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2006, and Form 10-QSB for the quarters ended March 31, 2007 and June 30, 2007, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements. HUMAN PHEROMONE SCIENCES, INC. Condensed Balance Sheets (Dollars in thousands) June 30, December 31, 2007 2006 (Unaudited) Assets Cash and cash equivalents $1,677 $1,941 Accounts receivable 171 39 Inventories, net 38 75 Other current assets 21 18 Property and equipment, net -- 2 Total assets $1,907 $2,075 Liabilities and shareholders' equity Accounts payable $ 36 $30 Other current liabilities 97 114 Deferred income - current 687 846 Deferred income - non-current 645 721 Common stock 20,904 20,865 Accumulated deficit (20,462) (20,501) Total liabilities and shareholders' equity $1,907 $2,075 HUMAN PHEROMONE SCIENCES, INC. Condensed Statements of Operations (Unaudited) (Dollars in thousands, except per-share data) Three months Six months ended June 30, ended June 30, 2007 2006 2007 2006 Net revenue $329 $184 $663 $450 Cost of goods sold 76 58 183 111 Research and development 16 35 28 59 Selling, general and administrative 238 247 446 507 Income (loss) from operations (1) (156) 6 (227) Other income 16 -- 34 1 Provision for income taxes -- -- 1 -- Net income (loss) $15 $(156) $39 $(226) Income (loss) per share, basic: $0.00 $(0.04) $0.01 $(0.05) Income (loss) per share, fully diluted: $0.00 $(0.04) $0.01 $(0.05) Weighted average common shares outstanding - Basic 4,152 4,152 4,152 4,152 Weighted average common shares outstanding - Fully diluted 4,805 4,152 4,794 4,152 Net income (loss) per share is based on the weighted average number of common shares and common share equivalents outstanding during each period. Certain common stock equivalents are excluded when their effect would be anti-dilutive. DATASOURCE: Human Pheromone Sciences, Inc. CONTACT: William P. Horgan, Chairman, CEO of Human Pheromone Sciences, Inc., +1-408-938-3030 Web site: http://www.naturalattraction.com/

Copyright